VIVUS (NASDAQ: VVUS) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare VIVUS to similar businesses based on the strength of its dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
Valuation & Earnings
This table compares VIVUS and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|VIVUS||$133.40 million||$67.14 million||2.76|
|VIVUS Competitors||$579.30 million||$241.72 million||-6.61|
Insider & Institutional Ownership
35.7% of VIVUS shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 4.4% of VIVUS shares are held by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent recommendations for VIVUS and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 6.23%. Given VIVUS’s peers higher probable upside, analysts plainly believe VIVUS has less favorable growth aspects than its peers.
Volatility & Risk
VIVUS has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, VIVUS’s peers have a beta of 1.28, meaning that their average stock price is 28% more volatile than the S&P 500.
This table compares VIVUS and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
VIVUS peers beat VIVUS on 6 of the 10 factors compared.
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
What are top analysts saying about VIVUS Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VIVUS Inc. and related companies.